Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Kind of Pet Makes the Incomparable Buddy? - 2Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- 3Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
- 4All that You Really want to Be familiar with Dental Inserts Facilities
- 5UK forecast to face weaker growth and higher inflation from Iran war
- Instructions to Guarantee Kids Foster Solid Dental Propensities
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- Israel scales back use of top missile interceptors as Iran barrages persist
- Ukraine Now Using Drone Boats To Attack Russian Riverine Targets
- Trump administration launches new immigration crackdowns in New Orleans and Minneapolis. Here are all the cities it has targeted so far.
- 'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- Air Canada CEO To Resign After Backlash—Here’s Why Communication Skills Is Now A Leadership Requirement
- Renewables cover over 50% of German electricity consumption in Q1
- 100 new alien worlds: Scientists find hidden haul in data from NASA exoplanet-hunting spacecraft
